|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CD24 |
Gene summary for CD24 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CD24 | Gene ID | 100133941 |
| Gene name | CD24 molecule | |
| Gene Alias | CD24A | |
| Cytomap | 6q21 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | B6EC88 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100133941 | CD24 | GSM4909280 | Human | Breast | Precancer | 4.31e-02 | -5.83e-01 | 0.0305 |
| 100133941 | CD24 | GSM4909281 | Human | Breast | IDC | 3.58e-56 | 6.40e-01 | 0.21 |
| 100133941 | CD24 | GSM4909285 | Human | Breast | IDC | 1.95e-05 | -3.40e-02 | 0.21 |
| 100133941 | CD24 | GSM4909286 | Human | Breast | IDC | 6.84e-11 | -2.25e-01 | 0.1081 |
| 100133941 | CD24 | GSM4909287 | Human | Breast | IDC | 5.21e-05 | 1.87e-01 | 0.2057 |
| 100133941 | CD24 | GSM4909289 | Human | Breast | IDC | 2.49e-30 | 8.22e-01 | 0.1064 |
| 100133941 | CD24 | GSM4909290 | Human | Breast | IDC | 4.63e-03 | 2.74e-01 | 0.2096 |
| 100133941 | CD24 | GSM4909293 | Human | Breast | IDC | 4.52e-25 | 4.63e-01 | 0.1581 |
| 100133941 | CD24 | GSM4909295 | Human | Breast | IDC | 9.58e-36 | 7.00e-01 | 0.0898 |
| 100133941 | CD24 | GSM4909296 | Human | Breast | IDC | 4.35e-11 | -4.51e-01 | 0.1524 |
| 100133941 | CD24 | GSM4909297 | Human | Breast | IDC | 8.12e-11 | -5.14e-03 | 0.1517 |
| 100133941 | CD24 | GSM4909298 | Human | Breast | IDC | 9.32e-23 | 4.56e-01 | 0.1551 |
| 100133941 | CD24 | GSM4909302 | Human | Breast | IDC | 8.68e-14 | -5.61e-01 | 0.1545 |
| 100133941 | CD24 | GSM4909304 | Human | Breast | IDC | 1.83e-44 | -9.02e-01 | 0.1636 |
| 100133941 | CD24 | GSM4909305 | Human | Breast | IDC | 6.80e-03 | 2.59e-01 | 0.0436 |
| 100133941 | CD24 | GSM4909306 | Human | Breast | IDC | 3.12e-23 | 4.52e-01 | 0.1564 |
| 100133941 | CD24 | GSM4909308 | Human | Breast | IDC | 1.16e-05 | -3.30e-01 | 0.158 |
| 100133941 | CD24 | GSM4909309 | Human | Breast | IDC | 1.47e-06 | -4.21e-01 | 0.0483 |
| 100133941 | CD24 | GSM4909311 | Human | Breast | IDC | 6.22e-27 | -7.57e-02 | 0.1534 |
| 100133941 | CD24 | GSM4909315 | Human | Breast | IDC | 1.37e-171 | 1.08e+00 | 0.21 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
| GO:00362939 | Breast | Precancer | response to decreased oxygen levels | 53/1080 | 322/18723 | 4.09e-12 | 6.84e-10 | 53 |
| GO:00016669 | Breast | Precancer | response to hypoxia | 51/1080 | 307/18723 | 7.33e-12 | 1.11e-09 | 51 |
| GO:00704829 | Breast | Precancer | response to oxygen levels | 55/1080 | 347/18723 | 7.47e-12 | 1.11e-09 | 55 |
| GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
| GO:00022378 | Breast | Precancer | response to molecule of bacterial origin | 43/1080 | 363/18723 | 6.05e-06 | 1.72e-04 | 43 |
| GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
| GO:00508707 | Breast | Precancer | positive regulation of T cell activation | 29/1080 | 216/18723 | 1.94e-05 | 4.58e-04 | 29 |
| GO:00436273 | Breast | Precancer | response to estrogen | 15/1080 | 75/18723 | 2.06e-05 | 4.83e-04 | 15 |
| GO:19030396 | Breast | Precancer | positive regulation of leukocyte cell-cell adhesion | 30/1080 | 239/18723 | 5.13e-05 | 1.07e-03 | 30 |
| GO:00508637 | Breast | Precancer | regulation of T cell activation | 37/1080 | 329/18723 | 8.04e-05 | 1.56e-03 | 37 |
| GO:00224098 | Breast | Precancer | positive regulation of cell-cell adhesion | 33/1080 | 284/18723 | 1.03e-04 | 1.89e-03 | 33 |
| GO:00071597 | Breast | Precancer | leukocyte cell-cell adhesion | 40/1080 | 371/18723 | 1.07e-04 | 1.94e-03 | 40 |
| GO:00457305 | Breast | Precancer | respiratory burst | 9/1080 | 37/18723 | 1.96e-04 | 3.10e-03 | 9 |
| GO:00224079 | Breast | Precancer | regulation of cell-cell adhesion | 45/1080 | 448/18723 | 2.12e-04 | 3.30e-03 | 45 |
| GO:19030377 | Breast | Precancer | regulation of leukocyte cell-cell adhesion | 36/1080 | 336/18723 | 2.61e-04 | 3.84e-03 | 36 |
| GO:00420987 | Breast | Precancer | T cell proliferation | 23/1080 | 199/18723 | 1.17e-03 | 1.27e-02 | 23 |
| GO:00421023 | Breast | Precancer | positive regulation of T cell proliferation | 14/1080 | 101/18723 | 1.94e-03 | 1.88e-02 | 14 |
| GO:00421296 | Breast | Precancer | regulation of T cell proliferation | 20/1080 | 171/18723 | 2.07e-03 | 1.97e-02 | 20 |
| GO:00506712 | Breast | Precancer | positive regulation of lymphocyte proliferation | 17/1080 | 137/18723 | 2.32e-03 | 2.16e-02 | 17 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| CD48 | CD244 | CD48_CD244A | CD48 | CRC | AD |
| CD48 | CD244 | CD48_CD244A | CD48 | CRC | MSI-H |
| CD48 | CD244 | CD48_CD244A | CD48 | CRC | SER |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CD24 | SNV | Missense_Mutation | novel | c.340N>C | p.Thr114Pro | p.T114P | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.952) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| CD24 | SNV | Missense_Mutation | novel | c.340A>C | p.Thr114Pro | p.T114P | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.952) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR | |
| CD24 | SNV | Missense_Mutation | novel | c.340A>C | p.Thr114Pro | p.T114P | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.952) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| CD24 | SNV | Missense_Mutation | novel | c.368C>A | p.Ser123Tyr | p.S123Y | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.873) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
| CD24 | SNV | Missense_Mutation | novel | c.340N>C | p.Thr114Pro | p.T114P | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.952) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |